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Combination therapy with interferon alpha (IFN- ) and α
ribavirin for 24 or 48 weeks according to HCV genotype has
improved the overall sustained virological response (SVR)
rates to approximately 40%. The aim of this study was to
investigate the long-term efficacy of combination therapy
with IFN- and ribavirin for chronic hepatitis C in Koreans. α
One hundred thirty-eight patients with chronic hepatitis C
who received this combination therapy between 1995 and
2003 were analyzed retrospectively. All patients were treated
with IFN- 3-6 million units three times weekly in com α -
bination with 900-1200 mg/day of ribavirin for 24 weeks.
The overall SVR rate was 41.3%. Patients were followed up
for a median of 41 months (range, 12-105 months) after
completion of therapy. In all of the SVR patients (57
patients), SVR was conserved during the follow-up period.
None of the patients progressed to decompensated liver
disease or hepatocellular carcinoma (HCC). However, 5 of
the 81 non-SVR patients (6.2%) progressed to decom-
pensated liver disease or HCC. In conclusion, combination
therapy with IFN- and ribavirin shows good long-term α
efficacy in patients with chronic hepatitis C in Korea, one of
the highest endemic areas of hepatitis B virus (HBV) infec-
tion.
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INTRODUCTION
Chronic hepatitis C infection affects nearly 170
million people worldwide, and it is the most com-
mon indication for liver transplantation.
1-3 Between
20 and 30% of infected individuals will eventually
go on to develop cirrhosis and its sequelae.
1-3 Un-
fortunately, even in developed countries, deaths
due to hepatitis C are increasing because of in-
adequate detection and treatment.
4-6 In a high
endemic area of HBV infection, chronic hepatitis
C may be overlooked until the disease has
progressed significantly. In Korea, which is a high
endemic area of HBV infection, about 50-90 thou-
sand people are chronically infected with HCV,
and at least 10-17% of hepatocellular carcinoma
(HCC) cases are probably attributable to HCV in-
fection.
7
The previous standard treatment for patients
infected with HCV before introduction of pegy-
lated IFN consisted of a combination of interferon
(IFN) and ribavirin, which lead to the elimination
of HCV-RNA and a long-term remission of the
liver disease in approximately 40% of patients.
8
There have been some studies which suggested
that treatment with the standard interferon-based
therapy resulted in a long-term moderate decrease
in HCC risk.
9-11 However, there have been few
reports on the long-term follow-up and rates of
HCC in patients who received the combination
therapy of interferon with ribavirin, especially in
high endemic areas of HBV infection. Our study
sought to address this question in Korean
patients.
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MATERIALS AND METHODS
Patients
We retrospectively reviewed the clinical data of
138 chronic hepatitis C patients who were serum
anti-HCV positive according to a third-generation
immunoenzyme assay, and HCV RNA positive by
a reverse transcriptase-polymerase chain reaction
(RT-PCR) using HCV specific primers. We ex-
cluded patients who had evidence of liver disease
due to any cause other than chronic hepatitis C,
decompensated liver disease-hypoalbuminemia
(albumin < 3.0 g/dL), jaundice (total bilirubin >
2.0 mg/dL), prothrombin time (PT) prolongation
(PT > 3 seconds), hepatic encephalopathy or
ascites-, other severe systemic disease, and preg-
nancy.
The patients were treated in the outpatient
clinic of Severance Hospital from January 1995 to
December 2003. We divided the 138 patients into
two groups, the initial treatment group and the
retreatment group. The initial treatment group
consisted of 94 patients, and the retreatment
group consisted of 44 patients who had pre-
viously received IFN monotherapy or IFN plus
ribavirin combination therapy.
All patients were treated for 24 weeks with
recombinant interferon alpha (Intermax- ; LG α
chemical Ltd, Korea: Intron- A; Schering-Plough,
Kenilworth, NJ, USA) plus ribavirin (Rebetol;
Schering-Plough, Kenilworth, NJ, USA). IFN-α
was administered subcutaneously three times
weekly (3-6 million units (MU)) and the ribavirin
was orally given 900 - 1200 mg/day. The safety,
tolerance and efficacy of the treatment were
assessed by interview and by biochemical and
hematological testing including serum -feto α pro-
tein and abdominal ultrasonography for screening
of HCC. Serum HCV-RNA concentrations were
measured before initiating treatment, 12 weeks
into the program, at the completion of therapy,
and every 24 weeks in the follow-up period.
Serum HCV RNA concentrations were measured
by PCR using a commercial assay with a lower
limit of detection of 50 IU/ml (Cobas Amplicor
HCV Monitor; Roche Diagnostics, Hoffman-
Laroche, Basel, Switzerland).
The IFN or ribavirin doses were modified if an
important adverse event occurred such as serious
alterations of renal function or hematological
toxicity.
Assessment of efficacy
In accordance with the NIH consensus state-
ment, the end of treatment response (ETR) was
defined as when a patient achieved undetectable
serum HCV RNA levels at the end of therapy. A
sustained virological response (SVR) was defined
as a persistent serum HCV RNA clearance for 24
weeks after the completion of therapy. A patient
was considered to have relapsed when the HCV
RNA was detected again after discontinuation of
treatment after it was reduced to undetectable
levels over the course of treatment. Patients for
whom HCV RNA levels remained detectable at
the end of treatment were considered nonre-
sponders (NR). Progression to decompensated
liver disease or development of HCC during the
follow-up period were included as possible long-
term outcomes of patients who received combina-
tion therapy.
Statistical analysis
The Chi square and the Fisher's exact test were
employed when necessary for comparison of
categorical variables, and the Student's t-test was
used for comparison of continuous variables.
Univariate and multivariate logistic regression
analyses were carried out to study the influence
of different variables on achievement of a SVR.
Differences were considered as significant when
the p-value was < 0.05. All calculations were per-
formed using the SPSS statistical package (SPSS
Inc., Chicago, IL, USA).
RESULTS
Ninety-four of the 138 patients (initial treatment
group) underwent IFN- plus ribavirin combina α -
tion therapy as their initial therapy and forty-four
patients (retreatment group) received retreatment
therapy. The patient characteristics of the two
groups are shown in Table 1. There were no sig-
nificant differences in age, gender, or baselineLong-Term Efficacy of IFN and Ribavirin
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laboratory findings between the two groups.
Virological response in initial and retreatment
patients
The proportions of patients grouped according
to the efficacies of both treatments are reported in
Table 2. For all the enrolled patients, a SVR was
observed in 57 of 138 patients (41.3%). There were
no significant differences in SVR (42.5% vs. 39%
respectively) between the initial and retreatment
groups. In the retreatment group, 20 patients had
been treated by previous IFN monotherapy and
24 patients had been treated by previous IFN plus
ribavirin combination therapy. The proportion of
patients grouped according to the efficacies of the
retreatment groups as categorized by previous
treatment responses is reported in Table 3. None
of nonresponders to previous combination
therapy had SVR on retreatment, whereas the SVR
of the other patients was comparable to the initial
treatment group.
Variables associated with SVR; pre-treatment and
on-treatment predictors
The SVR was unrelated to gender, age, baseline ALT
or biopsy stage before treatment
In this study, the on-treatment predictors for
response rates were analyzed as follows: out of
the 88 patients with ALT normalization at 4 weeks
after the initiation of therapy, 44 (32%) achieved
a SVR. Of the 50 patients with abnormal ALT
levels at 4 weeks, only 13 (9%) achieved a SVR
(Table 5). In a multivariate logistic model, ALT
normalization at 4 weeks after initiation of
Table 1. Base-line Characteristics of Patients
Initial treatment group
(n = 94, means ± SD)
Retreatment group
(n = 44, means ± SD)
Age (yrs) 49.8 ± 11.8 47.0 ± 11.4
Gender (male:female) 54 : 40 29 : 15
ALT (IU/L) 149 ± 96 151 ± 111
T. bilirubin (mg/dL) 0.7 ± 0.3 0.8 ± 0.3
Albumin (g/dL) 4.2 ± 0.3 4.3 ± 0.4
Prothrombin time (%) 98 ± 5 98 ± 3
Hemoglobin (g/dL) 13.9 ± 1.4 13.9 ± 1.4
White blood cell count (/ L) μ 5,367 ± 1,648 5,368 ± 1,226
Platelet count (× 10
3/ L) μ 157 ± 58 168 ± 59
p > 0.05 between initial treatment and retreatment groups.
ALT, alanine aminotransferase.
Table 2. Response Rates after Treatment According to ETR, SVR, and Relapse or NR
Total (n = 138) Initial treatment (n = 94) Retreatment (n = 44)
NR (%) 43 (31.2) 30 (32) 13 (30)
ETR (%) 95 (68.8) 64 (68) 31 (70)
SVR (%) 57 (41.3) 40 (42.5) 17 (39)
Relapse (%) 38 (27.5) 24 (25.5) 14 (31)
p, NS between two groups.
ETR, end of treatment response; SVR, sustained virological response; NR, no response.Jie-Hyun Kim, et al.
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therapy was significantly associated with a SVR (p
= 0.018) (Table 5).
Among the 83 patients who underwent testing
for HCV-RNA by PCR, 37 patients (45%) who
were negative for HCV-RNA at 12 weeks after
initiation of therapy achieved SVR. Thirty-seven
(63.8%) of the 58 patients who were negative for
HCV-RNA at 12 weeks after initiation of therapy
achieved a SVR (Table 5). Therefore, the predicta-
bility of the SVR based on the early virologic
response (EVR) was confirmed.
Tolerability and adverse events
No patients left the combination therapy trial
because of side effects. There were no differences
between the initial and retreatment groups in
their rates of dose modification. However, the side
effect profiles were higher in the initial treatment
Table 3. Treatment Responses in the Retreatment Group According to the ETR, SVR, and Relapse or NR
Previous interferon monotherapy (n = 20*) Previous combination therapy (n = 24 )
Relapse (n = 9) NR (n = 8) Relapse (n = 15) NR (n = 7)
NR (%) 2 (22.3) 1 (12) 4 (27) 5 (71)
ETR (%) 7 (77.7) 7 (88) 11 (73) 2 (29)
SVR (%) 3 (33.3) 5 (63) 6 (40) 0 (0)
Relapse (%) 4 (44.4) 2 (25) 5 (33) 2 (29)
*Previous response unknown in 3 patients (SVR = 2/3).
Previous response unknown in 2 patients (SVR = 1/2).
ETR, end of treatment response; SVR, sustained virological response; NR, no response.
Table 4. Long-term Follow-up Outcomes of SVR and Non-SVR Patients
SVR (n = 57) Non-SVR (n = 81)
Follow-up duration (median months) 34 (17 - 91) 44 (12 - 105)
Follow-up outcomes
SVR conservation without complication 57 (100%) 0
Relapse or no response without complication 0 76 (93.8%)
Decompensated liver disease 0 2 (2.5%)
Hepatocellular carcinoma 0 3 (3.7%)
SVR, sustained virological response.
Table 5. Multivariate Analysis of On-treatment Factors Associated with SVR
N (%) SVR rate (%) Odds ratio (95% CI) p
ALT at 4 weeks 138 4.17 (3.57 - 4.78) 0.018
Normal 88 (64) 44 (32)
Abnormal* 50 (36) 13 (9)
HCV RNA at 12 weeks 83 20.38 (19.58 - 21.18) < 0.001
Negative 58 (70) 37 (45)
Positive 25 (30) 2 (2)
*ALT > 46 IU/L.
SVR, sustained virological response; CI, confidence interval; ALT, alanine aminotransferase.Long-Term Efficacy of IFN and Ribavirin
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group than in the retreatment group (Table 6). For
hematologic side effects, which can be fatal, there
were no significant differences between the two
groups. The most common non-hematologic side
effect was general weakness.
Long-term clinical outcomes of combination therapy
In this study, patients were treated in our
outpatient clinics from January 1995 to December
2003, and followed up for mean period of 39
months after completion of therapy.
In all of the SVR patients (57 patients), SVR was
persistently conserved during the follow-up
period (median 34 months, 17-91 months). None
of the patients progressed to decompensated liver
disease or HCC during the follow-up period.
However, in the 81 non-SVR patients, 2 (2.5%)
patients progressed to decompensated liver dis-
ease and 3 (3.7%) progressed to HCC during the
median of 44 months (12-105 months) of follow-
up.
DISCUSSION
Combination therapy with IFN- and ribavirin α
for 24 or 48 weeks has improved the overall SVR
rates, which had been reported in previous major
trials as 31% to 47%.
1,9,12 In some studies, late
virological relapse, defined as the appearance of
detectable HCV RNA more than 24 weeks after
treatment with combination therapy,
13 occurred in
less than 1% of SVR patients.
13-15 In this study,
SVR was persistently conserved during an aver-
age follow-up period of 34 months.
The ultimate goal of anti-viral therapy for
chronic hepatitis C is to prevent HCC and im-
prove long-term prognosis. Some studies that
have addressed the long-term clinical outcomes of
interferon-based treatments.
9-11 Although the re-
sults were limited by the lack of randomized con-
trolled trials and substantial heterogeneity among
the retrospective and prospective group studies,
the evidence was generally consistent in sug-
gesting that treatment with standard interferon-
based therapy produced a moderate decrease of
the risk for HCC in the complete responders and
relapsed groups.
9-11 The potential benefits of
interferon therapy in preventing HCC may be due
to prevention of cirrhosis by interruption of the
inflammation and necrosis that accompanies
chronic hepatitis C, which generally resolves itself
in sustained virological responders.
14 Interferon
may exert a direct effect on cancer risk due to its
antiproliferative activity. Finally, interferon may
blunt the carcinogenic effects of viral replication
or intracellular viral proteins responsible for pro-
moting cell growth, proliferation, and malignant
transformation by suppressing viral replication.
16
To address the lack of long-term follow-up data
for combination therapy with interferon and riba-
virin, our study sought to investigate the long-
term clinical outcomes of responders and non-
responders to combination therapy with interferon
and ribavirin. However, the follow-up period of all
subjects was not consistent or well-matched, as this
was a retrospective study. The follow-up period
was longer in the non-responders. Therefore, more
follow-up data in responders is necessary for an
exact comparison with non-responders.
According to this study, none of 57 SVR patients
progressed to decompensated liver disease or
HCC. However, only 2 patients (5.3 %) among the
38 relapsers progressed to HCC and 3 patients (7.0
%) among 43 nonresponders progressed to de-
compensated liver disease or HCC. This fact
raised the possibility that standard interferon-
based combination therapy decreased the risk of
Table 6. Rates of Adverse Events or Dose Reduction
Initial treatment group
n = 94 (%)
Retreatment group
n = 44 (%)
p
Side effects 49 (52) 12 (27) 0.006
Hematologic 16 (17) 2 (5)
Others 33 (35) 10 (22)
Dose reduction 26 (28) 5 (11) 0.343Jie-Hyun Kim, et al.
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decompensated liver disease or HCC in the SVR
group. However, it is uncertain whether inter-
feron-based therapy that does not result in a SVR
has an effect in slowing the progression of disease
and the risk of HCC.
14 Some studies reported that
interferon had beneficial long term effects that
reduced the occurrence of HCC, even in patients
who did not have complete response to inter-
feron.
17 In one such study, retreament with IFN to
incomplete responders to previous IFN therapy
appeared to have the additional effect of sup-
pressing the development of HCC.
15 That study
suggested that IFN treatment had a suppressive
effect on disease progression even in patients
whose HCV was not eradicated with IFN. However,
more studies should be conducted regarding the
impact of interferon-based combination therapy
on the long-term outcomes of HCV non-eradi-
cated patients.
The recent treatment of choice for chronic
hepatitis C has been pegylated interferon (PEG-
IFN) plus ribavirin. In randomized-multinational
phase III clinical trials, PEG-IFN plus ribavirin
produced overall SVR rates of 56%
16 and 63%
17 in
initial treatment patients with chronic hepatitis C,
superior to the standard IFN plus ribavirin regi-
men. Therefore, further studies are warranted to
determine whether better results for long-term
clinical outcomes of HCV-infected patients can be
achieved with a combination therapy consisting of
PEG-IFN and ribavirin.
In conclusion, combination therapy with IFN-α
and ribavirin has a good long-term efficacy in
patients with chronic hepatitis C in Koreans, and
this treatment could decrease the risk of decom-
pensated liver disease or HCC in treatment
responders.
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